Stock Upgrades Today Highlight Top Momentum Plays

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  01 Dec 2025
 

•   ABBV  
   
  +0.16%
•   BKU  
   
  +0.52%
•   BROS  
   
  -0.52%
•   CCL  
   
  +0.12%
•   CMPX  
   
  +0.37%

$ABBV continues to capture attention as AbbVie increased outlook for 2025 and expansion plans have reinforced its strong buy rating. Trading at $225.11, the stock is slightly down 1.14% on modest volume of 2.86 million shares, but the fundamentals remain solid, with its product portfolio and pipeline expansions positioning it well for sustainable growth. Investors can view this as a confidence signal from analysts in AbbVie ability to execute on both earnings and strategic initiatives.

$BKU saw a 2.75% bump as BankUnited was upgraded by Jefferies from Hold to Buy. With the stock at $44.40 and trading on 814K shares, the move reflects increasing confidence in its balance sheet strength, credit quality, and growth prospects. Investors should consider the bank steady financial performance and potential for capital returns as part of their strategy.

$BROS remains an appealing consumer play as TD Cowen reiterated its Buy rating, highlighting a 29.37% upside. Trading at $59.36, Dutch Bros continues its uptrend on solid volume, reflecting strong brand loyalty and growth in consumer demand for its coffee offerings. Its positioning in the fast-growing specialty coffee market gives it a competitive edge among peers.

$CCL benefited from a Buy upgrade based on improving earnings prospects. Carnival shares moved up slightly to $25.93 on strong volume. Cruise industry optimism, fueled by increasing bookings and operational efficiencies, underpins this upgrade. While near-term volatility exists, the long-term trend for the travel and leisure sector remains positive.

$CMPX remains in focus as Compass Therapeutics secured analyst confidence due to its CTX-10726 advancement. Trading at $5.46, CMPX is down 5.86% but retains strong upside potential from its pipeline development. Investors seeking exposure to high-growth biotech should weigh both clinical milestones and volatility in decision-making.

$CVNA was upgraded to Outperform by Wedbush, reflecting the strength of Carvana fully online car retail model. At $375.26, the stock is slightly up on steady volume, showing investor confidence in the ability to scale and capture market share in the evolving automotive retail landscape.

$GSL is gaining attention after announcing acquisitions of three ECO-upgraded 8600 TEU containerships. Trading at $35.66, the stock is up 1.57%, signaling investor optimism in fleet expansion and efficiency improvements within the shipping sector.

$IIPR upgrade to Buy highlights the growing earnings optimism in the industrial real estate sector. With shares at $49.89, up 1.07%, investors see potential from stable lease structures and sector growth, making IIPR an attractive income-focused option.

$LDOS received a Buy upgrade based on its expected earnings improvement and strong position in defense and technology services. Trading at $188.42, the stock reflects investor confidence in contract wins and long-term government demand.

$NMRA saw a remarkable upgrade from Sector Perform to Outperform with projected upside of 287%. At $2.42, up 8.04%, Neumora Therapeutics presents one of the highest near-term growth opportunities among biotech plays, though it carries typical sector volatility.

$NMRK also benefits from a Buy rating upgrade, reflecting optimism in its real estate services operations. Trading at $17.25, the price minor pullback provides a potential entry for investors looking to capitalize on sector momentum.

$NUVB had its Buy rating reiterated, with 17.95% upside potential. At $7.88, Nuvation Bio remains an appealing biotech option with a strong development pipeline and high analyst confidence in growth prospects.

$RBRK received a Buy rating reflecting expected 2026 performance, trading at $68.60. While the stock is slightly down, analysts highlight its positioning and long-term growth potential.

$ROST continues its uptrend with a Buy upgrade, trading at $177.50. The stock reflects strong consumer retail performance and analyst optimism in continued sales growth.

$UBER despite a challenging market narrative around self-driving competition remains under observation following analyst coverage.

$ZS experienced downgrades and is less compelling in the current trading environment.

View All Headlines